Calidi Biotherapeutics(CLDI) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results - Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs - Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company's Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the Nationa ...